This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
The Heart of Earnings Season: Global Week Ahead
by John Blank
Quarterly results could push the combined market capitalization of the FAANGs -- Facebook, Amazon, AAPL Netflix and Google-parent Alphabet -- back above their all-time peak of $6.16 trillion.
New Highs for Stocks with More Big Earnings Reports to Come.
by David Borun
Big Technology stocks led the broad markets to additional gains and a new POTUS is inaugurated.
Johnson & Johnson, Boeing, Facebook, Apple and Tesla are part of Zacks Earnings Preview
by Zacks Equity Research
Johnson & Johnson, Boeing, Facebook, Apple and Tesla are part of Zacks Earnings Preview
Q4 and 2021 Earnings Estimates Keep Going Up
by Sheraz Mian
We are off to a great start in the Q4 earnings season, with a historically high proportion of the reporting companies not only beating consensus EPS and revenue estimates, but also providing positive guidance and commentary...
Regional Banks Post Mixed Earnings Results
by Zacks Equity Research
Regional Banks Post Mixed Earnings Results.
Q4 Earnings Come to Regional Banks: ALLY, HBAN & More
by Mark Vickery
Most of the Big Banks have already posted for Q4; this morning we see a large share of Regional Banks reporting quarterly earnings.
Glaxo (GSK) Gets FDA Nod for Long-Acting HIV Regimen Cabenuva
by Zacks Equity Research
Glaxo (GSK) and J&J's (JNJ)get FDA approval for Cabenuva, a once-monthly injectable regimen of cabotegravir and rilpivirine, for the treatment of adults with virally suppressed HIV-1 infection.
J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while continued procedure stabilization is expected to have benefited the Medical Devices segment in the fourth quarter.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $162.38, marking a -0.25% move from the previous day.
J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis
by Zacks Equity Research
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $160.65, moving +1.75% from the previous trading session.
Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag
by Zacks Equity Research
Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $158.13 in the latest trading session, marking a -0.78% move from the prior day.
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene
by Zacks Equity Research
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan
by Zacks Equity Research
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
Johnson & Johnson (JNJ) Stock Moves -0.42%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $159.37, marking a -0.42% move from the previous day.
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
by Zacks Equity Research
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
Racing Against Time: Covid-19 vs. Vaccines
by Mark Vickery
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
Xencor (XNCR) Inks Deal for Novel Antibody Therapies in Cancer
by Zacks Equity Research
Xencor (XNCR) signs a strategic research collaboration deal with MD Anderson Cancer Center to develop and commercialize T Cell-engaging bispecific antibodies for treating cancer.
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease
by Zacks Equity Research
If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.